Disclosure

In the initial public offering of Orexo AB, Carnegie Fund Management Company S.A. has acquired 900,000 shares and now owns 6.78 per cent of the capital and voting rights in the company. The holding is distributed among three equity mutual funds; Carnegie Medical, Carnegie Global Healthcare and Carnegie Biotechnology. For further information please contact Carl Harald Jansson, portfolio manager, on telephone +46 8 5886 9152 or e-mail: carjan@carnegie.se.